key: cord-0805618-cmi404b7 authors: Quast, Isaak; Tarlinton, David title: B cell memory: Understanding COVID-19 date: 2021-01-23 journal: Immunity DOI: 10.1016/j.immuni.2021.01.014 sha: 0bc105f21d26e0aa9634d66e14c78f91e6bd7abe doc_id: 805618 cord_uid: cmi404b7 Immunological memory is a mechanism to protect us against reinfection. Antibodies produced by B cells are integral to this defence strategy and underlie virtually all vaccine success. Here we explain how B cells memory is generated by infection and vaccination, what influences its efficacy and its persistence and how characterising these parameters in the immune response to SARS-CoV-2 will help achieve protective immunity through vaccination. 2 long memory confers immunity and the requirements for generating and sustaining such memory, be that from infection or vaccination, are challenging but critical questions to be answered in understanding how to prevent infection. Memory is a cardinal feature of so-called adaptive immune responses, which are those involving lymphocytes, key cells of the immune system. When an infection triggers a lymphocyte response, it induces a small number of pre-existing B and T cells (two types of lymphocytes) to proliferate, creating a small army of cells specific for, and thus able to combat, the infectious agent. B and T cells are triggered to respond by recognizing a part of the pathogen through their antigen receptors with a certain strength. Each B cell and T cell expresses on their surface an antigen receptor that is different to all others, such that all possible invaders have their own, pre-existing, matching B and T cells ready to respond if and when required. During the response, some pathogen-specific B cells are induced to differentiate and secrete their antigen receptors into the blood in form of antibodies (Abs), which circulate through the body, binding to the pathogen that triggered the response wherever it occurs. Once the pathogen has been subdued and the response is effectively over, most pathogen-specific B and T cells die, but a small number of these recent combatants -B cell, T-cells and antibody secreting plasma cells (PC) -persist as specialised, long-lived immune memory cells. In responding to infection, our immune system uses information from the pathogen to determine the scale and composition of the response so as to efficiently combat the pathogen, minimising the energetic cost of the response and the risk of collateral damage to self. This includes selecting for those B-cells with the highest binding strength (affinity) for their specific targets (antigens) on the pathogen. It is from among these "best of the best" that immune memory cells are recruited. Ideally, re-infection by a pathogen would not require a repeat immune response as Ab secreted by persisting PC could bind to the pathogen and block its lifecycle at the outset. These pathogen-specific Abs would act as a shield against reinfection. If the amount of Ab in circulation drops, or if the pathogen varies from the initial infection, the shield may not be protective and a rerun of the response would be required. This response, triggered by re-exposure to the same or a closely related pathogen, uses the memory B and T cells, incorporating the information acquired in the first 3 response by starting with cells that have already been selected as being strongly reactive. This head-start makes memory responses faster, larger and of higher affinity than the initial response, allowing for rapid negation of the pathogen, often before symptoms develop. Given that an immune response is a life-or-death battle for a pathogen, microbes have evolved mechanisms to avoid or minimise recognition by the immune system and many demonstrate co-evolution with immune responses. For example, a successful Ab response against a virus may focus on one specific target, called an epitope. If a virus mutates the epitope so it is no longer efficiently recognised by Ab, the variant may escape and be able to infect other individuals irrespective of their immunity to the initial strain. This could be prevented if there was sufficient breadth of recognition among the memory cells to react to the variant. Thus, while creating a memory of the initial pathogen is a crucial part of immunity, immune memory should have both specificity and the capacity to adapt to potential diversification of its targets. One of the most effective immune defence mechanisms of our body is the secretion of high affinity Abs. Part of the effectiveness of Ab is that over the course of an infection, its affinity for antigen (binding strength) improves and its class or isotype (immunoglobulin (Ig) M, IgG, IgA, IgE) changes, enabling enable Abs to better bind to and neutralise pathogens. Isotype refers to the section of the Ab that does not directly bind antigen, but rather triggers other PC produced by the GC ultimately reside in spleen and bone marrow where they can survive in specialised niches for periods of years to decades, continuously secreting Ab independently of pathogen presence. This circulating Ab will be protective as long as the amount is sufficient to neutralise a pathogen inoculum without activating an immune response and without symptoms developing ( Figure 2 ) -the amount depending on Ab affinity as well as the size of the inoculum. What controls the persistence of PC, and thus the duration of Ab production, remains largely unknown but there is a strong association between the type of immune response and the durability of the PC produced; viral infections typically produce very long-lived PC while vaccines based on components of the virus (subunit vaccines) tend to be less long-lived. In addition, and irrespective of whether or not the Ab is neutralising, PC-derived Ab will decorate its target (opsonize), aiding recognition by other components of the immune system and if required, promoting a secondary immune response ( Figure 2 ). These outcomes are dictated to an extent by the isotype of the Ab bound to the pathogen as different Ab classes activate different aspects of J o u r n a l P r e -p r o o f the immune response. Ab class switching is directed by soluble mediators (cytokines) secreted by the CD4 + T cells that 'help' the B cells in the early stages of the response ( Figure 1 ). The cytokine profile of CD4 + T cells, established during their initial activation, is based on invariant characteristics of the pathogen and the infection. By programming CD4 + T cells using attributes of the pathogen, information about the pathogen is reflected in the class of Ab the B cells, PB, memory B cells and PC produce. In this way, the most useful effector properties of the immune system are recruited for each infection independently of Ab specificity and affinity. Ab class also influences Ab half-life and tissue distribution. In contrast to sessile PC, MBC recirculate through the body and can be rapidly activated following reinfection to produce Ab-secreting PB or initiate secondary GC (Figure 1 ). This can occur if the amount of Ab in circulation is insufficient to block the new infection or if infection is by a variant of the initial pathogen that has escaped recognition by the existing, highly specific Ab. MBC can respond to variants because as a population they possess a broader spectrum of affinity and reactivity than is present in the long-term secreted Ab, even incoporating the initial reactivity (Figure 1, left) . MBC can rapidly initiate a secondary GC reaction and produce PB secreting Ab that will promote antigen capture and feedforward to amplify the secondary responses. These new GC can also drive improved affinity for the variant pathogen, producing fresh MBC and PC with improved specificity and affinity for the new challenge. Where long-lived PC have diminished to the point that Ab is insufficient for neutralising immunity (Figure 2 ), the response starts with MBC that have a higher affinity and are more frequent than in the first response, so establishing protective amounts of Ab of the correct class is significantly faster than in the initial response. mTfh function as do MBC in that their presence increases the likelihood and speed of secondary Ab responses. The mechanism of pathogen recognition by CD4 + T cells is very different to that of B cells, relying on linear protein determinants that are mostly distinct from the Ab's recognition sites. The linked but distinct recognition by B cells and CD4 + T cells combating the same pathogen fosters breadth and flexibility of the response, provides resilience against immune evasion and offers a safety check on inappropriate immune responses, maximising the likelihood of maintaining immunity (Figure 2 ). Ensuring the survival of the host is the principal goal of an immune response and the formation of memory is subordinate to the course of infection. For example, if innate defence mechanisms are sufficient to hold an infection at bay, then an adaptive immune response will likely not be triggered and, as a result, lasting immunity may not be achieved. This comes at the cost of host susceptibility to re-infection and reflects a strategy for pathogens to keep circulating without the need for adaptation. When an adaptive immune response is initiated, the selection of Ab targets on the pathogen is guided by their physical properties and the host's immune repertoire (the diversity of antigen recognition receptors). Not every epitope is the target of an Ab response and many viruses and bacteria have evolved to hide their most vulnerable regions, hindering effective neutralizing immune responses. So, having Ab specific to a pathogen does not imply immunity -the Ab has to be directed at appropriate targets that are retained unaltered by the pathogen. For example, influenza virus infection generates Ab responses that target several viral epitopes, some of which will block infection while others do little. For the influenza strain to successfully spread, it must alter those sites that are the targets of neutralising Abs, but it can leave the remaining targets unaltered. Thus, although flu-specific Abs may be present, they may not block host infection. There is an important caveat to this; evading neutralisation by changing a site targeted by the immune response is only possible to the extent that the alteration doesn't interfere with the pathogen's life cycle. Often structures or proteins critical to the pathogen's lifecycle are invariant and conserved across related viral strains. Thus, Abs that recognise such targets can confer protection against multiple variants and are referred to as broadly-neutralising (BN-Ab). As we've discussed, pathogens can disguise these sites, meaning that BN-Ab are often not generated or only after prolonged infection as these hidden epitopes may require many rounds of B-cell mutation and selection in the GC to achieve an Ab with sufficient affinity to be neutralising. Perhaps paradoxically, the opportunity for the immune system to generate Bn-Ab may not arise if Ab that target other epitopes rapidly neutralise the infection ( Figure 3A ). Another important parameter of the immune response, and therefore immunological memory, is the site of infection such as respiratory tract, blood or gut. For Ab, this can be reflected in choice of isotype (e.g. IgA is predominantly secreted into the mucosa while IgG circulates in blood and lymphatics) and site of memory PC persistence (gut, spleen, BM). Pathogens do not necessarily complete their entire life cycle at one location and both site and mechanism of initial entry may be independent of the remainder of the infection. Therefore, generating an immune response that prevents infection from happening may not necessarily be achieved by an immune response that targets a late-stage infection as at that point, entry into the host is not a criterion for host survival. Many characteristics of an immune response are determined by the type of infection, however, diversity in crucial immune system components and age-related immune dysfunction can lead to variability in the immune response in each individual to the one pathogen. In an extreme form, a virus may be controlled by one person's immune system yet be fatal to another. More generally it means there will be variation within a population in the quality and quantity of the immune response to a pathogen, a variability that will also occur in response to vaccination. Finding the right vaccine formulation and vaccination schedule to ensure a strong and long-lasting response that induces protective immune memory in as many individuals as possible is crucial for vaccine success ( Figure 3B ). Vaccines given in the absence of infection can utilise delivery schedules that promote lengthy immune responses to achieve long-lived protective immunity as host survival at that time does not require rapid eradication of the pathogen. While current vaccination strategies can generate durable memory in the vast majority of individuals, there are groups such as the elderly and immunosuppressed who show poor immune responses to both vaccination and infection, which often correlates with being most at risk of severe disease, as currently exemplified by COVID-19. By analysing responses to infection, we know that immunity operating through Ab has to comprise Ab reactivity that (1) limits the pathogen life cycle, (2) activates other components of the immune system evolved to negate the pathogen, (3) is distributed to appropriate parts of the body, (4) has sufficient affinity so that relatively low amounts of Ab will be effective in neutralising a pathogen inoculum, and ideally, (5) should be produced for many years. Immunity to infection requires an appropriate form of immunological memory at the time of re-exposure. For a pathogen that is primarily controlled by Ab, this can be either sufficient Ab in bodily fluids to supress infection at the outset, or it can be memory B and T J o u r n a l P r e -p r o o f 8 cells combining to rapidly produce the PB that will then secrete protective Ab. The central questions with regard to immunity to SARS-CoV-2 infection are: Does infection or vaccination lead to the production of immune memory that will neutralise future infection? And, how long does protection last and is it capable of recognising variants of SARS-CoV-2 that arise in the population? We are still early in characterising immune responses to SARS-CoV-2 and its vaccine candidates, meaning we lack the systematic population studies required to determine the full extent of protection provided by previous infection or vaccination. Encouragingly, confirmed reports of re-infection are very rare and Abs induced by either infection or vaccine candidates include known neutralizing specificities. That is, there is every reason to be optimistic of immunity to SARS-CoV-2 developing from infection and from vaccination. The vast majority of people recovering from SARS-CoV-2 infection developed T cell and B cell memory. The memory B cells found in recovered patients up to 6 months post infection produced Abs that neutralised SARS-CoV-2, indicating they could produce PC secreting protective Ab when restimulated. Remarkably, one recent study noted MBC increased in number and affinity in the 6 months post infection, implying an ongoing immune response despite the apparent clearance of the virus. Despite these findings, the novelty of SARS-CoV-2 means that uncertainty remains as to the durability of Ab production, reflected in contrasting studies noting Ab declines or sustained production. But even if Ab amounts diminish over time, it appears very likely that persistent MBC and T cells will rapidly produce additional, even improved Ab, on re-exposure. Definitive assessment of these aspects of immunity will require examination of COVID-19 patients several years post recovery, measuring specific Ab and memory B and T cells and correlating these with re-infection. Understanding the requirements for Ab to neutralise SARS-CoV-2 is of major importance in predicting immunity following either infection or vaccination. If SARS-CoV-2 infection takes a severe course GC formation is impaired, which will impact affinity maturation and memory quality and quantity, but it is unclear if this occurs during mild or asymptomatic infection. Having said that, the Ab structure required for neutralising SARS-CoV-2 may not be particularly complex as several of the reported neutralizing Ab contained few mutations, suggesting they can be generated in relatively short-term GC. Another encouraging aspect is J o u r n a l P r e -p r o o f that coronaviruses 'proof-read' their relatively large genome to maintain integrity, thereby limiting diversification, which is in contrast to most other RNA viruses that continuously evolve by mutating their genome. Nevertheless, some naturally occurring and experimental SARS-CoV-2 variants did circumvent neutralisation by specific Ab while retaining infectivity. Importantly, these cases did not represent escape from the totality of anti-SARS-CoV-2 Ab present in serum of recovered patients, but rather from a single species of Ab. While this emphasises the value of the diversity of the immune response to SARS-CoV-2, it also shows why monitoring closely the viral strains circulating in communities is critical, so as to adjust vaccines if required. A hallmark of immune responses to pathogens is to create a memory of the response, which is the persistence of small numbers of pathogen-specific B and T cells and the plasma cells that secrete pathogen-specific Ab. Immune memory may block future infections without symptoms developing either by continued production of neutralizing Abs from long-lived PC, or if that Ab amount diminishes, by recalling memory B and T cells to rapidly produce new PB and thus restore high affinity, neutralizing Ab in circulation. Protection from infection is also generated through vaccination, relying also on the continued or restored production of pathogen specific, neutralizing Ab. The key challenges in establishing protective immune memory to a pathogen are producing high-affinity neutralizing Abs; maintaining production of such Abs; and counteracting any ongoing variability of the pathogen. The immune system has evolved to address these issues in the generation of memory, including affinity maturation in GC; potentially life-long survival of PC in specialised niches; and breadth of reactivity in memory B cells. While these attributes frequently occur in response to infection, establishing PC -and thus Ab -longevity through vaccination remains inconsistent. Overall, however, the prospects of widespread immunity to SARS-CoV-2, either by infection or vaccination, appear to be very strong with durability being the remaining unknown, which can only be answered with time. the Swiss National Science Foundation and a Peter Doherty Early Career fellowship (APP1145136) provided by NHMRC Australia. The authors declare no competing interests. In an infection primarily controlled by Abs, protective immunity depends on the quantity and quality of available Ab, MBC and mTfh cells. The presence of sufficiently high amounts of neutralizing Abs will result in sterilizing immunity, negating the requirement for a recall response. If the production of neutralizing Ab is insufficient or has waned and thus exceeded by the pathogen load, an infection will occur. The remaining neutralizing Ab will still limit the extent of infection and both neutralizing and non-neutralizing Ab will facilitate the initiation of secondary immune responses by increasing the visibility of the pathogen to the IS (opsonization). If circulating Ab has dropped below effective levels, the initial pathogen entry can occur largely unchecked resulting in an infection of increased speed and magnitude before MBC and mTfh cells can provide protection via a recall response. In some J o u r n a l P r e -p r o o f cases, 'Ab' memory may completely dissipate, resulting in susceptibility to full-blown infection and the requirement for a primary immune response. Ab, antibody; PB, plasmablast; MBC, memory B cell; GC, germinal centre; mTfh, Follicular helper memory T cell. (A) The initial diversity of B cell reactivities participating in an immune response is high while their antigen binding affinity is generally low. During this pre-GC phase, pre-GC MBC and short-lived PB differentiate (producing low-affinity Abs). Once the GC reaction commences, affinity-based selection results in an increase in Ab affinity while the diversity of targeted epitopes decreases. This is due to limited availability of resources (e.g. antigen, T cell help) that favours dominant epitopes to which high affinity Ab can be rapidly generated. Once the GC reaches maximal Ab affinity, the response starts to re-diversify, now allowing more sub-dominant epitopes to be targeted. The probability of generating high-affinity neutralizing Abs increases rapidly during the first phase of the GC reaction, but BN-Abs often require prolonged immune responses due to their epitopes being sub-dominant. The response output as staged; early on, rapid PB generation and MBC differentiation while later, once affinity increases, long-lived PC are generated. GC, germinal centre; Ab, antibody; BN-Ab, broadly-neutralizing Ab; MBC, memory B cells; mTfh, Follicular memory T cells; PB, plasmablasts. (* when most CD4 Tmem cells differentiate is still largely unknown) (B) The immune response following vaccination is usually short-lived with the magnitude depending on the individual's immune system. To achieve vaccine efficacy in a large fraction of the population, booster vaccination is often applied, recalling the memory cells already generated. The increased magnitude and duration of a secondary response improves memory generation to the point of sufficient quantity and quality for protection. J o u r n a l P r e -p r o o f B cell memory: building two walls of protection against pathogens Mechanisms that determine plasma cell lifespan and the duration of humoral immunity T follicular helper cell differentiation, function, and roles in disease Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19 The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants Herd Immunity: Understanding COVID-19 How intrinsic and extrinsic regulators of plasma cell survival might intersect for durable humoral immunity Functional SARS-CoV-2-specific immune memory persists after mild COVID-19 Germinal center selection and the antibody response to influenza Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants Memory B Cells of Mice and Humans Investigator Award to DT (APP1175411) and IQ by an Early Postdoc Mobility fellowship